扎鲁司特联合沙美特罗替卡松气雾剂对小儿咳嗽变异性哮喘症状改善及肺功能的影响

Effect of zafirlukast combined with salmeterol cinafoate and fluticasone propionate aerosol on symptom improvement and pulmonary function of children with cough variant asthma

目的研究扎鲁司特联合沙美特罗替卡松气雾剂对小儿咳嗽变异性哮喘(CVA)症状改善及肺功能的影响。方法 360例CVA患儿,采用随机数字表法分为研究组和对照组,各180例。对照组采用沙美特罗替卡松气雾剂治疗,研究组于对照组基础上联合扎鲁司特治疗。比较两组治疗效果,临床症状改善时间,治疗前后肺功能指标[第1秒用力呼气容积(FEV1)、呼气峰流量(PEF)、第1秒用力呼气容积/用力肺活量(FEV1/FVC)]。结果研究组治愈109例,显效45例,有效21例,无效5例,总有效率为97.22%(175/180);对照组治愈81例,显效38例,有效33例,无效28例,总有效率为84.44%(152/180);研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。研究组咳嗽缓解时间(4.19±1.35)d、咳嗽消失时间(6.53±1.86)d均短于对照组的(6.28±1.64)、(8.29±1.75)d,差异有统计学意义(P<0.05)。治疗前,两组FEV1、PEF、FEV1/FVC水平比较,差异无统计学意义(P>0.05)。治疗后,研究组FEV1(1.89±0.25)L、PEF(88.26±7.59)%、FEV1/FVC(90.64±6.13)%均高于对照组的(1.51±0.22)L、(81.37±7.18)%、(82.37±6.96)%,差异有统计学意义(P<0.05)。结论扎鲁司特联合沙美特罗替卡松气雾剂治疗CVA患儿的疗效显著,能有效改善患儿肺功能,促进症状消失,具有较高应用价值。

Objective To study the effect of zafirlukast combined with salmeterol cinafoate and fluticasone propionate aerosol on symptom improvement and pulmonary function of children with cough variant asthma(CVA).Methods A total of 360 CVA children were randomly divided into research group and control group,with 180 cases in each group.The control group was treated with salmeterol cinafoate and fluticasone propionate aerosol,and the research group was treated with zafirlukast on the basis of the control group.The therapeutic effect,clinical symptom improvement time,pulmonary function indicators[forced expiratory volume in the first second(FEV1),peak expiratory flow(PEF),FEV1/forced vital capacity(FEV1/FVC)]before and after treatment were compared between the two groups.Results In the research group,there were 109 cure cases,45 excellent cases,21 effective cases and 5 ineffective cases,with total effective rate as 97.22%(175/180).In the control group,there were 81 cure cases,38 excellent cases,33 effective cases and 28 ineffective cases,with total effective rate as 84.44%(152/180).The total effective rate of treatment of the research group was higher than that of the control group,and the difference was statistically significant(P<0.05).The cough remission time(4.19±1.35)d and cough disappearance time(6.53±1.86)d of the research group were shorter than(6.28±1.64)and(8.29±1.75)d of the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in FEV1,PEF and FEV1/FVC between the two groups(P>0.05).After treatment,FEV1(1.89±0.25)L,PEF(88.26±7.59)%and FEV1/FVC of the research group were higher than(1.51±0.22)L,(81.37±7.18)%and(82.37±6.96)%of the control group,and the difference was statistically significant(P<0.05).Conclusion Zafirlukast combined with salmeterol cinafoate and fluticasone propionate aerosol shows remarkable efficacy for CVA children,and it can effectively improve the pulmonary function and promote the disappearance of symptoms.It contains high practical value.